Opinion|Videos|July 16, 2024
Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.
Advertisement
Episodes in this series
- In addition to cost, what factors influence coverage decisions for AD treatments?
- How do step-therapy protocols and prior authorization approval process influence the prescribing patterns of topical therapies (and progressing to systemic therapies) for AD among healthcare providers?
- What strategies can healthcare providers implement to streamline the PA approval process for topical AD therapies and reduce administrative burdens while still ensuring cost-effective care?
- Please discuss the burden providers face in terms of workload perspective, staffing constraints, etc, and what this means for patients
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
emtelligent Turns Unstructured Clinical Data Into Actionable Insights
2
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, but Longer Follow-Up Needed: Rahul Banerjee, MD
5